Centene Corporation (CNC)
Centene: High-Risk Buy With Huge Potential
Centene Corporation faces high costs and near-term profitability challenges, but offers significant long-term upside if margins recover. CNC's Q3 earnings are expected to be volatile, with revenue likely beating estimates but bottom-line results remaining pressured by cost headwinds. The company can potentially restore profitability by adjusting premiums over time, though margin recovery is expected to be gradual, not immediate.
These 3 worst-performing stocks of 2025 could be your best buying opportunity
While the broader S&P 500 has enjoyed a resilient 2025 with consistent record highs, some individual names have suffered heavy losses.
Top Stock Movers Now: Centene, Micron Technology, Oracle, and More
U.S. equities gained at midday, with the S&P 500 and Nasdaq adding to Wednesday's latest closing record highs, as new inflation and unemployment reports boosted confidence the Federal Reserve will cut interest rates next week. The Dow Jones Industrial Average was more than 1% higher.
Are Strategic Contracts and Partnerships Centene's Growth Engine?
Centene's growth hinges on government contracts and strategic partnerships, but shares have plunged over 52% this year.
Centene: Be Greedy When Others Are Fearful
Centene's stock is deeply undervalued after a 60% drop, with key valuation multiples 50%-70% below historical averages. Despite 2025 headwinds and EPS guidance cuts, Centene remains profitable, well-diversified, and financially stable with strong liquidity. Long-term demographic trends and Centene's history of resilience support a sharp EPS rebound in 2026 and 2027.
Centene Faces HBR Pressures: Will Scale Support Stability?
CNC's rising HBR, driven by higher medical costs and policy shifts, pressures margins as it leans on scale and efficiency for stability.
Is CNC Banking on Membership Growth to Boost Scale & Profitability?
Centene's growing membership base boosts revenue scale and operational efficiency, even as medical inflation puts pressure on margins.
One Big Beautiful Bill Act: A Boon or Bane for Centene?
CNC faces both risk and reward from the One Big Beautiful Bill Act as Medicaid cuts collide with digital reform gains.
Centene Loses 57% YTD, Incurs Loss in Q2: How to Play the Stock
CNC plunges 57% YTD after its first quarterly loss in over a decade, with analysts slashing 2025 earnings outlook by 70%.
Centene's Bottom May Already Be Here - Risk Mitigation In Process
CNC has offered FY2025 adj EPS range at between $1.25 (-82.5% YoY) and $1.75 (-75.5% YoY), as medical costs rise drastically and higher morbidity sign-ups replace a healthier base. These have directly triggered the drastically lower consensus forward estimates, with the healthcare providers expected to report impacted, new normal profit margins. Despite so, readers must note that CNC is already engaging on risk mitigation while driving improved profitability through rate adjustments from 2026 onwards.
Centene's Worst Quarter In Years Could Be A Gift
Centene's Q2 results were ugly but better than feared, with losses largely expected and a visible path to recovery emerging. Management is aggressively addressing ACA and Medicaid margin pressures, with rate adjustments and reratings expected to restore profitability by 2026. Valuation remains highly attractive, trading at under 7x PE, offering potential for the stock to double as earnings rebound and multiples normalize.
Time To Buy Centene Stock?
Centene (NYSE:CNC) recently reported a surprise loss of $0.16 per share for Q2, significantly missing analyst expectations of $0.23 per share. This downturn is primarily attributed to a continued increase in medical costs for government-backed insurance plans, evidenced by a 540 basis point year-over-year surge in its health benefit ratio to 93% in Q2.
